Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 6
1991 2
1992 2
1993 1
1994 3
1995 2
1996 2
1997 5
1999 6
2000 2
2001 4
2002 5
2003 7
2004 3
2005 6
2006 3
2007 5
2008 4
2009 1
2010 1
2011 2
2012 1
2013 5
2014 5
2015 7
2016 10
2017 5
2018 3
2019 5
2020 6
2021 4
2022 6
2023 6
2024 6
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Protein Coaggregation in Caribbean Atypical Parkinsonism: The Contribution of Annonacin.
González-Lizárraga F, Boluda S, Hidalgo JR, Avila CL, Santos CD, Socias B, Medina L, Chaumont H, Akbar D, Roze E, Chehin R, Raisman-Vozari R, Michel PP, Lannuzel A. González-Lizárraga F, et al. Among authors: michel pp. Neuropathol Appl Neurobiol. 2025 Aug;51(4):e70026. doi: 10.1111/nan.70026. Neuropathol Appl Neurobiol. 2025. PMID: 40702589 Free PMC article.
4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.
Dos Santos Pereira M, Dias de Abreu GH, Vanderlei LCA, Raisman-Vozari R, Guimarães FS, Lu HC, Michel PP, Del Bel E. Dos Santos Pereira M, et al. Among authors: michel pp. Neuropharmacology. 2024 Jun 15;251:109926. doi: 10.1016/j.neuropharm.2024.109926. Epub 2024 Mar 28. Neuropharmacology. 2024. PMID: 38554815 Free PMC article.
Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Olanow CW, et al. Among authors: michel pp. Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243. Mov Disord. 2004. PMID: 15372588 Review.
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak P, Tolosa E, et al. Agid Y, et al. Among authors: michel pp. Mov Disord. 1999 Nov;14(6):911-3. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h. Mov Disord. 1999. PMID: 10584663 Review. No abstract available.
134 results